GSTA3: Glutathione S-Transferase Alpha 3

A key enzyme in detoxification and antioxidant defense, with implications in cancer and metabolic disorders.

Gene Information Card

Symbol GSTA3
Full Name Glutathione S-Transferase Alpha 3
Gene Type Protein coding
Chromosomal Location 6p12.2
NCBI Gene ID 2940 ncbi.nlm.nih.gov/gene/2940
Ensembl ID ENSG00000174156
UniProt ID Q16772
OMIM ID 138360
HGNC ID 4629
Aliases GSTAA3, GSTA3-3, GTA3

Description

GSTA3 (Glutathione S-Transferase Alpha 3) is a protein-coding gene belonging to the alpha class of glutathione S-transferases (GSTs). These enzymes catalyze the conjugation of reduced glutathione to a wide variety of electrophilic compounds, playing a critical role in cellular detoxification, antioxidant defense, and metabolism of xenobiotics and endogenous substances. GSTA3 is expressed in multiple tissues, with highest levels in liver, kidney, and adrenal gland. It is involved in the metabolism of steroid hormones and lipid peroxidation products, and its dysregulation has been linked to various cancers and metabolic diseases.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Hepatocellular Carcinoma Altered GSTA3 expression may affect detoxification of carcinogens and oxidative stress response, contributing to liver carcinogenesis. PMID: 25642768
Colorectal Cancer Reduced GSTA3 expression is associated with increased oxidative DNA damage and tumor progression. PMID: 28411313
Type 2 Diabetes GSTA3 polymorphisms and altered expression may influence oxidative stress and insulin resistance. PMID: 27346398

Expression Profile

Tissue Expression
Tissue nTPM level
Liver 124.2 High
Kidney 45.6 Medium
Adrenal Gland 38.1 Medium
Small Intestine 22.4 Medium
Lung 8.9 Low
Heart 5.2 Low
Cell Line Expression
Cell Line nTPM Notes
HepG2 98.7 Hepatocellular carcinoma cell line
HEK293 12.3 Embryonic kidney cells
A549 6.8 Lung carcinoma cell line
MCF7 4.1 Breast cancer cell line
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.313G>A (p.Gly105Arg) Missense 0.01% Reduced catalytic activity; associated with altered drug metabolism
c.419C>T (p.Thr140Met) Missense 0.005% Unknown functional effect; rare population variant
c.1A>G (p.Met1Val) Start loss <0.001% Loss of protein expression; potential loss-of-function
Mutation functional classification

Loss of Function (LOF)

Start loss mutation (p.Met1Val) and missense variant p.Gly105Arg reduce or abolish enzymatic activity, impairing detoxification capacity.

Gain of Function (GOF)

No gain-of-function mutations have been reported for GSTA3 in the curated databases.

Dominant Negative (DN)

No dominant-negative mutations have been described for GSTA3.

Pathways

Glutathione metabolism (KEGG: hsa00480)
Metabolism of xenobiotics by cytochrome P450 (KEGG: hsa00980)
Drug metabolism - cytochrome P450 (KEGG: hsa00982)
Chemical carcinogenesis (KEGG: hsa05204)

Protein Summary

GSTA3 encodes a 222-amino acid protein (25.5 kDa) that functions as a homodimer. Each subunit contains a glutathione-binding site (G-site) and a hydrophobic substrate-binding site (H-site). The enzyme catalyzes the conjugation of reduced glutathione to electrophilic substrates, including carcinogens, therapeutic drugs, and products of oxidative stress. GSTA3 also exhibits steroid isomerase activity, converting delta5-androstene-3,17-dione to delta4-androstene-3,17-dione. The protein is predominantly cytosolic and highly expressed in liver, kidney, and adrenal tissues. Post-translational modifications include phosphorylation and S-nitrosylation, which modulate its activity.

Related Products

Product name Cat.No. Species Gene ID
GSTA3 Knockout HEK293 Cell Line EDJ-KQ4804 Human 2940 Details Get a Quote
GSTA3 Knockout HeLa Cell Line EDJ-KQ53450 Human 2940 Details Get a Quote
GSTA3 Knockout A-549 Cell Line EDJ-KQ61924 Human 2940 Details Get a Quote
GSTA3 Knockout HCT 116 Cell Line EDJ-KQ70403 Human 2940 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: